Outcomes Summary for Mesenchymal Stem Cell (MSC) Therapy

The available evidence for MSC therapy outcomes is limited and primarily comes from preclinical studies, with sparse clinical trial data available for review.

Reported Measurable Results

Cardiovascular Applications:
Recent preclinical research suggests human amniotic MSCs may have cardioprotective properties, though specific outcome measures are not detailed in the available evidence.

Liver Regeneration:
Laboratory studies indicate that MSC-derived hepatocytes, when primed with compounds like quercetin, may enhance liver regeneration. However, quantitative regeneration metrics are not specified in the current evidence.

Wound Healing and Tissue Repair:
Preclinical research shows MSCs may influence wound repair through multiple mechanisms:

Enhanced angiogenesis (blood vessel formation)
Fibroblast activity modulation
Immunoregulatory effects

The evidence suggests MSC secretome (released factors) can be reprogrammed to drive these repair processes, though specific biomarker changes or healing timeframes are not quantified.

Musculoskeletal Applications:
Studies examining chondrogenic (cartilage-forming) potential of adipose-derived and dental pulp-derived MSCs show promise for tissue engineering applications, but measurable clinical outcomes are not reported.

Inflammatory Conditions:
Limited evidence suggests MSC-derived extracellular vesicles may reduce inflammation in certain disease models, with one study specifically noting effects in Sandhoff disease models.

Clinical Trial Evidence

The clinical evidence is extremely sparse. Available trials include:

Phase 2 study for female sexual dysfunction (status unknown)
Phase 1/2 study for cerebellar ataxia (completed, outcomes not reported)
Phase 2 study for lupus nephritis (status unknown)
Phase 1 study for erectile dysfunction in diabetic patients (status unknown)

Strength of Evidence

The evidence base is notably weak. Most available data comes from preclinical laboratory studies rather than controlled human trials. The few clinical trials identified either have unknown status or lack reported outcomes. No standardized outcome measures, biomarker panels, or consistent efficacy metrics are established across studies.

Important considerations:

Lack of standardized MSC preparation and delivery methods
Potential for tumor cell resistance mechanisms in cancer applications
Limited safety and efficacy data from completed human studies

This information is for educational purposes only and should not be considered medical advice. Patients considering MSC therapy should consult with qualified healthcare providers to discuss potential risks, benefits, and alternative treatments.

Mesenchymal Stem Cell (MSC) Therapy

Member access required